Johnson & Johnson (JNJ)vsMeiraGTx Holdings PLC (MGTX)
JNJ
Johnson & Johnson
$275.19
+1.53%
HEALTHCARE · Cap: $615.87B
MGTX
MeiraGTx Holdings PLC
$9.71
-0.46%
HEALTHCARE · Cap: $884.56M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 24890% more annual revenue ($99.33B vs $397.50M). MGTX leads profitability with a 19.9% profit margin vs 16.2%. MGTX trades at a lower P/E of 10.7x. MGTX earns a higher WallStSmart Score of 61/100 (C+).
JNJ
Buy57
out of 100
Grade: C
MGTX
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-83.0%
Fair Value
$144.12
Current Price
$275.19
$131.07 premium
Intrinsic value data unavailable for MGTX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 25.1%
Generating 6.4B in free cash flow
Attractively priced relative to earnings
Every $100 of equity generates 37 in profit
Strong operational efficiency at 76.0%
Revenue surging 8609.0% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 96.0%
0.0% earnings growth
Smaller company, higher risk/reward
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.1%.
Bull Case : MGTX
The strongest argument for MGTX centers on P/E Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 19.9% and operating margin at 76.0%. Revenue growth of 8609.0% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Bear Case : MGTX
The primary concerns for MGTX are EPS Growth, Market Cap, Free Cash Flow.
Key Dynamics to Monitor
JNJ profiles as a mature stock while MGTX is a growth play — different risk/reward profiles.
MGTX carries more volatility with a beta of 1.35 — expect wider price swings.
MGTX is growing revenue faster at 8609.0% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
MGTX scores higher overall (61/100 vs 57/100), backed by strong 19.9% margins and 8609.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →MeiraGTx Holdings PLC
HEALTHCARE · BIOTECHNOLOGY · USA
MeiraGTx Holdings plc, a clinical-stage gene therapy company, focused on developing treatments for patients living with serious illnesses. The company is headquartered in New York, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?